Zafar Hayat, Habibullah Khan, Iftikhar Ahmad, Hafsa Habib, Khizar Hayat


Brucellosis is the most common zoonotic bacterial infection in the world. The causative organism is Brucella spp. and the incubation of period is 5 days to 5 months. Although immunological tests are widely used for the diagnosis but cultures of the blood or other clinical specimens is the gold standard for the diagnosis. Outbreaks of brucellosis occur from time to time. It spreads mostly in the communities having close contact with the sheep and cattle, like farmers, cattle grazers, veterinary workers, and butchers. In the urban situation the outbreaks usually occur due to consumption of unpasteurized milk or its products. The clinical features of brucellosis are protean but the major one is a prolonged fever. Infected animals are the reservoirs and the sources of infection. Antibiotics have a major role in the management of brucellosis. Although a single antibiotic may be effective but a combination is preferred to prevent the chances of development of resistance and recurrence of disease. Antibiotics commonly used in the management of brucellosis are doxycycline, rifampicin, streptomycin, fluoroquinolones, cotrimoxazole, and chloramphenicol. Resistance to one or the other antibiotic have been reported from time to time. Dual therapy is commonly prescribed and triple therapy is used in serious conditions like neuro-brucellosis, endocarditis, or recurrence. The objective of this review was to evaluate the effects of various antibiotic regimens in the management of brucellosis. Antibiotic resistance is a problem which can aggravate the situation in future. We suggest that antibiotics’ use should be rationalized to prevent future drug resistance. At least dual therapy should be used to prevent the chances of recurrence and triple therapy for complicated cases and in cases of relapse. There should be no compromise on the optimal doses and duration of therapy.


Brucellosis; Antimicrobial susceptibility; Antibiotics; Antimicrobials; Brucella mellitensis; Brucella abortus.

Full Text:



Morand S, McIntyre KM, Baylis M. Domesticated animals and human infectious diseases of zoonotic origins: domestication time matters. Infect Genet Evol 2014; 24:76-81.

Cross AR, Baldwin VM, Roy S, Essex-Lopresti AE, Prior JL, Harmer NJ. Zoonoses under our noses. Microbes Infect 2019; 21:10-9.

McGregor AC, Moore DA. Infectious causes of fever of unknown origin. Clin Med 2015; 15:285-7.

Hull NC, Schumaker BA. Comparisons of brucellosis between human and veterinary medicine. Inf Ecol Epidemiol 2018; 8:1500846.

Kohlera S, Ouahrani-Bettachea S, Winumb J. Brucella suis carbonic anhydrases and their inhibitors: towards alternative antibiotics? J Enz Inhibit Medhem 2017; 32:683-7.

Brucellosis in humans and animals.: WHO guidance. Geneva, World Health Organization, 2005. Heymann DL (ed.). Control of communicable diseases manual: an official report of the American Public Health Association. 18th ed. Washington DC, World Health Organization/American Public Health Association, 2004.

Centers for Disease Control and Prevention. Suspected Brucellosis Case Prompts Investigation of Possible Bioterrorism-Related Activity-New Hampshire and Massachusetts, 1999. MMWR June 16, 2000; 49(23):509-512.

Plumb GE, Olsen SC, Buttke D. Brucellosis: ‘One Health’ challenges and opportunities. Rev Sci Tech Off Int Epiz 2013; 32:271-8.

Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012; 10: CD007179.

Tsevelmaa N, Narangerel B, Odgerel O, Dariimaa D, Batkhuu J. Anti-brucella activity of Caryopteris mongolica Bunge root extract against Brucella melitensis infection in mice. BMC Compl Alt Med 2018; 18:144.

Solís García del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One 2012; 7: e32090.

Bukhari EE. Pediatric brucellosis - an update review for the new millennium. Saudi Med J 2018; 39:336-41.

Liu Z, Di D, Wang M, Liu R, Zhao H, Piao D, et al. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China. BMC Infect Dis 2018; 18:43. doi: 10.1186/s12879-018-2947-6

Somily AM, Alahaideb A, Ridha A, Syyed S, Shakoor Z, Fatani A, et al. Clinical and therapeutic features of brucellosis: an 11-year study at a tertiary care hospital in Riyadh, Saudi Arabia. Trop Biomed 2017; 34:1-6.

Shevtsov A, Syzdykov M, Kuznetsov A, Shustov A, Shevtsova E, Berdimuratova K, et al. Antimicrobial susceptibility of Brucella melitensis in Kazakhstan. Antimicrob Res Inf Cont 2017; 6:130.

Meng F, Pan X, Tong W. Rifampicin versus streptomycin for brucellosis treatment in humans: a meta-analysis of randomized controlled trials. PLoS ONE 2018; 13(2): e0191993.

Kesli R, Bilgin H, Yilmaz H. Determination of in vitro susceptibilities of Brucella spp. Strains abainst 11 different antibacterial agents isolated from blood cultures. Mikrobiyol Bul 2017; 51:260-8.

Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004; 23:405-7.



  • There are currently no refbacks.

Copyright (c) 2020 Habibullah Khan, Iftikhar Ahmad, Hafsa Habib, Khizar Hayat

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Gomal Medical College, Daraban Road, Dera Ismail Khan, Pakistan

ISSN: 1819-7973, e-ISSN: 1997-2067


Phone: +92-966-747373

Scimago Journal & Country Rank